BioIntelligence is coordinated by Dassault Systèmes, and involves life science companies including sanofi-aventis, Ipsen, Servier, Pierre Fabre, Bayer Cropscience, along with public research institutes including Inserm, Inria and Genopole, and small bioinformatics specialists such as Aureus and Sobios. €46.3 million of the project’s funding comes from OSEO, the French agency responsible for supporting innovation and growth of SMEs.
BioIntelligence will borrow the technique of Product Lifecycle Management, used by manufacturing industries, to optimise drug discovery process. Aureus will participate in the development of the Knowledge Management layer of the planned system, building new content in therapeutic areas including oncology, nuclear receptors, proteases inhibitors and life science semantics.
In addition to providing significant funding, Aureus says this work will enable it to evolve its data models, integrating more complex information on drug properties, biological protocols and the regulation of physiological responses. In total, the company expects to receive €3.5 million for its contribution.
“We are excited at the opportunity working with such prestigious partners in the Biointelligence consortium,” said Jason Theodosiou, President & CEO of Aureus Pharma. “This programme confirms the key contribution of Aureus’ know-how in the development of knowledge-driven information systems in the life science industry.”
Receive our Policy Bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
